EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Glycaemic, cardiorenal, and lipid parameters associated with SGLT2 inhibitors use in Indonesian patients with type 2 diabetes: 12-month multicenter real-world study

Fonny Cokro iD, Rani Sauriasari iD, Dicky Levenus Tahapary, Heri Setiawan, Christian Tricaesario, Nurul Hidayati, William Djauhari, Jimmy Tandradynata iD, Sidartawan Soegondo

PLOS One · 2026

DOI: 10.1371/journal.pone.0353564 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift PLOS One, 2026. Verfasst von Fonny Cokro und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Social Pharmacy Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Lipids, Blood Glucose. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lembaga Pengelola Dana Pendidikan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have demonstrated efficacy in glycaemic control and cardiorenal protection across multiple meta-analyses. However, their applicability to the Indonesian population remains uncertain due to demographic, lifestyle, and healthcare disparities. This study aims to evaluate the effectiveness of SGLT2is in managing metabolic control, cardiorenal risk factors, and their safety relative to non-SGLT2is in the T2DM population in Indonesian real clinical settings.

Methods

This study applied a multicenter retrospective cohort design, enrolling adult Indonesian T2DM patients who had received treatment for at least 12 months. Intragroup paired analysis and intergroup comparative studies were performed regarding metabolic control, cardiorenal, and safety parameters.

Results

A total of 638 patients were included, with 319 patients contributing to paired analyses. In paired data analysis, SGLT2is significantly improved HbA1c, fasting plasma glucose (FPG), body weight, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), lipid profile, and atherosclerotic cardiovascular disease (ASCVD) risk (p < 0.05). Compared to non-SGLT2is, SGLT2is are associated with greater reductions in HbA1c, FPG, body weight, BMI, and SBP. Although no intergroup differences were observed in other parameters, adjusted analyses revealed additional benefits of SGLT2is in lowering low-density lipoprotein (LDL) cholesterol and maintaining estimated Glomerular Filtration Rate (eGFR), though SBP effects became nonsignificant. No major safety signals were observed.

Conclusion

These findings support the use of SGLT2is as effective agents for improving glycaemic control, body weight, blood pressure, lipid profile, and ASCVD risk in Indonesian patients with T2DM. Further studies are warranted to clarify their safety, long-term renal effects, and to explore the comparative effects of individual SGLT2is and dosing strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsLipidsBlood GlucoseHumansFemaleMiddle AgedIndonesiaMaleRetrospective StudiesGlycated HemoglobinBlood PressureAgedAdult

Substanzen

Sodium-Glucose Transporter 2 InhibitorsLipidsBlood GlucoseGlycated Hemoglobin

Autor:innen und Institutionen

  • Clinical and Social Pharmacy Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia.
  • Department of Pharmacy, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
  • Health Innovation Study and Policy Research Cluster, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia.
  • Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, Dr. Cipto Mangunkusumo National Referral Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
  • Metabolic, Cardiovascular, and Aging Cluster, The Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
  • Department of Pharmacology, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia.

ORCID-Profile: Fonny Cokro, Rani Sauriasari, Jimmy Tandradynata

Förderung

  • Lembaga Pengelola Dana Pendidikan

Zitieren

APA

Cokro, F., Sauriasari, R., Tahapary, D. L., Setiawan, H., Tricaesario, C., Hidayati, N., Djauhari, W., Tandradynata, J., & Soegondo, S. (2026). Glycaemic, cardiorenal, and lipid parameters associated with SGLT2 inhibitors use in Indonesian patients with type 2 diabetes: 12-month multicenter real-world study. PLOS One. https://doi.org/10.1371/journal.pone.0353564

Vancouver

Cokro F, Sauriasari R, Tahapary DL, Setiawan H, Tricaesario C, Hidayati N, et al. Glycaemic, cardiorenal, and lipid parameters associated with SGLT2 inhibitors use in Indonesian patients with type 2 diabetes: 12-month multicenter real-world study. PLOS One. 2026. doi:10.1371/journal.pone.0353564

BibTeX
@article{Cokro2026,
  author = {Cokro, Fonny and Sauriasari, Rani and Tahapary, Dicky Levenus and Setiawan, Heri and Tricaesario, Christian and Hidayati, Nurul and Djauhari, William and Tandradynata, Jimmy and Soegondo, Sidartawan},
  title = {Glycaemic, cardiorenal, and lipid parameters associated with SGLT2 inhibitors use in Indonesian patients with type 2 diabetes: 12-month multicenter real-world study},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0353564}
}
Kostenlos starten →